lanthanum carbonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4585 587-26-8

Description:

MoleculeDescription

Synonyms:

  • lanthanum carbonate
  • fosrenol
a phosphate binder used for hyperphosphatemia treatment in end-stage renal disease
  • Molecular weight: 457.84
  • Formula: C3La2O9
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 63.19
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2.25 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 2008 PMDA Bayer Yakuhin
Oct. 26, 2004 FDA SHIRE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Shunt stenosis 361.26 23.60 53 3439 506 90624449
Shunt occlusion 262.74 23.60 42 3450 733 90624222
Nephrogenic systemic fibrosis 132.89 23.60 31 3461 4077 90620878
Peritonitis 84.88 23.60 31 3461 19674 90605281
Blood phosphorus increased 80.83 23.60 21 3471 4297 90620658
Skin induration 71.53 23.60 18 3474 3244 90621711
Blood parathyroid hormone increased 51.41 23.60 14 3478 3423 90621532
Skin hypertrophy 50.73 23.60 14 3478 3596 90621359
Hyperphosphataemia 50.35 23.60 14 3478 3697 90621258
Skin tightness 47.72 23.60 14 3478 4474 90620481
Peripheral arterial occlusive disease 42.98 23.60 13 3479 4608 90620347
Death 41.90 23.60 68 3424 456483 90168472
Skin fibrosis 41.20 23.60 9 3483 879 90624076
Angina unstable 33.60 23.60 12 3480 7131 90617824
Sepsis 32.04 23.60 37 3455 179777 90445178
Hypocalcaemia 31.79 23.60 20 3472 42348 90582607
Shunt malfunction 31.55 23.60 5 3487 82 90624873
End stage renal disease 31.46 23.60 12 3480 8559 90616396
Joint contracture 30.41 23.60 8 3484 1714 90623241
Ileus 29.91 23.60 14 3478 16532 90608423
Sleep disorder therapy 28.64 23.60 6 3486 480 90624475
Dialysis 28.22 23.60 12 3480 11317 90613638
Scar 27.75 23.60 13 3479 15382 90609573
Blood calcium increased 27.50 23.60 12 3480 12046 90612909
Analgesic therapy 26.70 23.60 6 3486 666 90624289
Vomiting 26.27 23.60 78 3414 788215 89836740
Antacid therapy 26.02 23.60 6 3486 748 90624207
Appendicolith 25.96 23.60 6 3486 755 90624200
Drug therapy 25.60 23.60 6 3486 803 90624152
Anticoagulant therapy 25.54 23.60 6 3486 811 90624144
Peritonitis bacterial 25.50 23.60 9 3483 5162 90619793
Cardiac failure 23.76 23.60 25 3467 109471 90515484

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 559.68 28.51 194 12796 13262 42595083
Appendicitis 499.85 28.51 200 12790 20413 42587932
Shunt stenosis 397.97 28.51 82 12908 695 42607650
Stress 373.43 28.51 207 12783 44005 42564340
Cardiogenic shock 368.71 28.51 191 12799 35449 42572896
Ventricular fibrillation 365.96 28.51 180 12810 29943 42578402
Abdominal distension 313.65 28.51 221 12769 71514 42536831
Ascites 310.85 28.51 201 12789 56477 42551868
Hyperphosphataemia 283.51 28.51 117 12873 12887 42595458
Myasthenia gravis 268.78 28.51 120 12870 16017 42592328
Shunt occlusion 250.55 28.51 59 12931 968 42607377
Multiple organ dysfunction syndrome 250.44 28.51 219 12771 96816 42511529
Hyponatraemia 245.96 28.51 221 12769 101241 42507104
Sleep disorder therapy 231.88 28.51 85 12905 6809 42601536
Analgesic therapy 214.11 28.51 79 12911 6445 42601900
Incorrect route of product administration 213.75 28.51 117 12873 24188 42584157
Hypophosphataemia 192.98 28.51 104 12886 20841 42587504
Blood uric acid increased 191.88 28.51 94 12896 15453 42592892
General physical health deterioration 185.48 28.51 229 12761 151017 42457328
Drug therapy 179.39 28.51 69 12921 6311 42602034
Neuralgia 178.55 28.51 106 12884 25541 42582804
Bacterial infection 178.02 28.51 109 12881 27770 42580575
Constipation 168.04 28.51 226 12764 162065 42446280
Dry mouth 162.80 28.51 118 12872 39761 42568584
Blood cholesterol increased 156.68 28.51 99 12891 26642 42581703
Sepsis 154.50 28.51 242 12748 199092 42409253
Activated partial thromboplastin time prolonged 149.36 28.51 80 12910 15823 42592522
Abdominal pain 147.25 28.51 231 12759 190240 42418105
End stage renal disease 140.82 28.51 78 12912 16480 42591865
Antacid therapy 139.73 28.51 53 12937 4664 42603681
Ulcer 133.14 28.51 75 12915 16366 42591979
Anticoagulant therapy 130.89 28.51 50 12940 4485 42603860
Iron deficiency 130.86 28.51 65 12925 10996 42597349
Blood calcium increased 109.94 28.51 53 12937 8401 42599944
Diabetes mellitus 109.47 28.51 112 12878 59975 42548370
Hyperlipidaemia 107.24 28.51 72 12918 21444 42586901
Chronic obstructive pulmonary disease 104.88 28.51 112 12878 63002 42545343
Swelling 103.06 28.51 104 12886 54781 42553564
Vomiting 99.50 28.51 250 12740 289473 42318872
Intentional product misuse 96.13 28.51 106 12884 61794 42546551
Sleep disorder 95.58 28.51 94 12896 48001 42560344
Gout 94.41 28.51 74 12916 27981 42580364
Aortic stenosis 93.51 28.51 48 12942 8697 42599648
Congenital hiatus hernia 93.50 28.51 43 12947 6131 42602214
Thrombosis 92.31 28.51 109 12881 68402 42539943
Bronchopulmonary aspergillosis allergic 92.17 28.51 39 12951 4559 42603786
Troponin increased 86.01 28.51 60 12930 19002 42589343
Acute kidney injury 85.98 28.51 7 12983 367330 42241015
Blood test abnormal 78.61 28.51 49 12941 12857 42595488
X-ray abnormal 77.24 28.51 20 12970 492 42607853
Somnolence 75.87 28.51 146 12844 140959 42467386
Drug intolerance 66.75 28.51 101 12889 80323 42528022
Bacteroides infection 62.23 28.51 25 12965 2562 42605783
Pleuritic pain 61.96 28.51 34 12956 7043 42601302
Aspiration 59.77 28.51 47 12943 17839 42590506
Drug hypersensitivity 58.55 28.51 107 12883 99282 42509063
Total lung capacity decreased 57.63 28.51 26 12964 3544 42604801
Nausea 57.63 28.51 256 12734 396543 42211802
Peripheral arterial occlusive disease 54.81 28.51 31 12959 6807 42601538
Product residue present 53.31 28.51 23 12967 2818 42605527
Cardiovascular disorder 48.75 28.51 37 12953 13328 42595017
Micturition urgency 48.02 28.51 35 12955 11863 42596482
Breath sounds abnormal 47.51 28.51 35 12955 12058 42596287
Nephrogenic systemic fibrosis 45.66 28.51 22 12968 3479 42604866
Shunt infection 45.28 28.51 10 12980 121 42608224
Pulmonary embolism 44.86 28.51 107 12883 119505 42488840
Blood phosphorus increased 44.20 28.51 34 12956 12491 42595854
Respiratory symptom 43.30 28.51 32 12958 11074 42597271
Joint injury 41.52 28.51 35 12955 14641 42593704
Toxicity to various agents 40.54 28.51 10 12980 229126 42379219
Hypercholesterolaemia 39.17 28.51 32 12958 12817 42595528
Condition aggravated 39.06 28.51 170 12820 260584 42347761
Rash 38.76 28.51 18 12972 276936 42331409
Drug interaction 36.37 28.51 18 12972 266981 42341364
Benign prostatic hyperplasia 36.05 28.51 38 12952 21014 42587331
X-ray gastrointestinal tract abnormal 35.48 28.51 5 12985 0 42608345
Fatigue 33.24 28.51 51 12939 435590 42172755
Weight decreased 33.22 28.51 11 12979 207937 42400408
Lung opacity 32.63 28.51 21 12969 5816 42602529
Peritonitis 32.56 28.51 34 12956 18599 42589746
Hyperparathyroidism secondary 31.60 28.51 14 12976 1828 42606517
Neutropenia 31.07 28.51 11 12979 199420 42408925
Anaemia 30.64 28.51 167 12823 280111 42328234
Lower respiratory tract infection 30.32 28.51 49 12941 41157 42567188
Febrile neutropenia 29.35 28.51 10 12980 185693 42422652
Dialysis hypotension 28.98 28.51 6 12984 52 42608293

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Shunt stenosis 743.03 26.23 135 15745 1281 110572138
Appendicolith 719.68 26.23 200 15680 14055 110559364
Appendicitis 614.77 26.23 208 15672 28256 110545163
Shunt occlusion 487.96 26.23 98 15782 1639 110571780
Ventricular fibrillation 468.71 26.23 188 15692 41125 110532294
Cardiogenic shock 441.03 26.23 198 15682 57140 110516279
Hyperphosphataemia 398.47 26.23 131 15749 16250 110557169
Ascites 378.06 26.23 208 15672 92600 110480819
Stress 372.03 26.23 215 15665 105133 110468286
Myasthenia gravis 348.56 26.23 127 15753 21384 110552035
Sleep disorder therapy 318.87 26.23 92 15788 7379 110566040
Multiple organ dysfunction syndrome 318.76 26.23 223 15657 151487 110421932
Abdominal distension 298.91 26.23 227 15653 174876 110398543
Analgesic therapy 294.49 26.23 86 15794 7198 110566221
Hyponatraemia 261.57 26.23 230 15650 217423 110355996
Hypophosphataemia 253.09 26.23 114 15766 33068 110540351
Blood uric acid increased 251.04 26.23 100 15780 21429 110551990
Drug therapy 250.87 26.23 76 15804 7215 110566204
Sepsis 241.82 26.23 265 15615 327081 110246338
Bacterial infection 231.97 26.23 119 15761 45917 110527502
End stage renal disease 216.96 26.23 90 15790 21383 110552036
Incorrect route of product administration 216.03 26.23 127 15753 63934 110509485
Neuralgia 209.25 26.23 113 15767 48365 110525054
Activated partial thromboplastin time prolonged 200.15 26.23 86 15794 22282 110551137
Antacid therapy 196.57 26.23 59 15821 5425 110567994
Constipation 187.14 26.23 243 15637 357543 110215876
Anticoagulant therapy 184.94 26.23 56 15824 5305 110568114
General physical health deterioration 167.41 26.23 252 15628 425043 110148376
Iron deficiency 165.18 26.23 71 15809 18405 110555014
Abdominal pain 147.80 26.23 264 15616 512725 110060694
Diabetes mellitus 145.88 26.23 118 15762 99263 110474156
Gout 143.32 26.23 80 15800 36486 110536933
Hyperlipidaemia 142.06 26.23 79 15801 35769 110537650
Chronic obstructive pulmonary disease 138.24 26.23 119 15761 109039 110464380
Thrombosis 134.65 26.23 117 15763 108545 110464874
Blood calcium increased 134.40 26.23 61 15819 17979 110555440
Ulcer 131.08 26.23 80 15800 43036 110530383
Aortic stenosis 129.42 26.23 54 15826 13005 110560414
Congenital hiatus hernia 128.16 26.23 44 15836 6215 110567204
Troponin increased 127.33 26.23 69 15811 29697 110543722
Peripheral arterial occlusive disease 107.77 26.23 43 15837 9237 110564182
Intentional product misuse 107.34 26.23 113 15767 132791 110440628
Bronchopulmonary aspergillosis allergic 104.70 26.23 41 15839 8385 110565034
Nephrogenic systemic fibrosis 102.44 26.23 36 15844 5447 110567972
Somnolence 101.18 26.23 165 15715 297284 110276135
Vomiting 92.89 26.23 314 15566 910361 109663058
Blood test abnormal 91.98 26.23 55 15825 28499 110544920
Dry mouth 86.41 26.23 124 15756 199824 110373595
Product residue present 85.75 26.23 29 15851 3912 110569507
Aspiration 83.55 26.23 53 15827 30480 110542939
Peritonitis 82.80 26.23 54 15826 32553 110540866
Bacteroides infection 81.76 26.23 26 15854 2893 110570526
Total lung capacity decreased 79.27 26.23 32 15848 7082 110566337
Benign prostatic hyperplasia 69 26.23 39 15841 18195 110555224
Blood cholesterol increased 68.94 26.23 107 15773 184678 110388741
Pulmonary embolism 68.86 26.23 116 15764 214358 110359061
Shunt infection 67.74 26.23 14 15866 271 110573148
Blood phosphorus increased 64.69 26.23 36 15844 16304 110557115
Pleuritic pain 62.37 26.23 35 15845 16105 110557314
Acute kidney injury 61.61 26.23 9 15871 635421 109937998
Anaemia 59.45 26.23 193 15687 546893 110026526
Micturition urgency 59.08 26.23 36 15844 19284 110554135
Blood parathyroid hormone increased 57.50 26.23 22 15858 4226 110569193
Respiratory symptom 56.64 26.23 32 15848 14913 110558506
Cardiovascular disorder 56.09 26.23 37 15843 22723 110550696
Lung opacity 55.42 26.23 29 15851 11623 110561796
Sleep disorder 55.39 26.23 101 15779 198543 110374876
Arthralgia 52.80 26.23 23 15857 779609 109793810
Breath sounds abnormal 52.40 26.23 37 15843 25367 110548052
Joint swelling 51.54 26.23 3 15877 442842 110130577
Fatigue 50.93 26.23 60 15820 1215898 109357521
Skin induration 49.76 26.23 20 15860 4375 110569044
Nausea 46.19 26.23 319 15561 1235371 109338048
Weight increased 45.51 26.23 4 15876 419640 110153779
Rash 44.39 26.23 32 15848 820932 109752487
Skin hypertrophy 43.80 26.23 19 15861 5028 110568391
Angina unstable 43.65 26.23 28 15852 16404 110557015
Cerebral infarction 43.46 26.23 45 15835 51793 110521626
Transaminases increased 42.63 26.23 49 15831 63341 110510078
Shunt aneurysm 42.24 26.23 7 15873 36 110573383
Haemoglobin increased 41.33 26.23 22 15858 9125 110564294
Alopecia 40.87 26.23 3 15877 364750 110208669
X-ray gastrointestinal tract abnormal 40.18 26.23 6 15874 13 110573406
Toxicity to various agents 37.91 26.23 11 15869 480544 110092875
Joint injury 37.70 26.23 37 15843 39957 110533462
Aplasia pure red cell 37.63 26.23 21 15859 9557 110563862
Hyperparathyroidism secondary 37.29 26.23 15 15865 3289 110570130
Hypocalcaemia 36.54 26.23 46 15834 65320 110508099
Hypersensitivity 36.29 26.23 7 15873 403991 110169428
Coronary artery disease 36.24 26.23 48 15832 71642 110501777
Peritonitis bacterial 35.77 26.23 21 15859 10512 110562907
Diverticulum intestinal haemorrhagic 35.13 26.23 16 15864 4747 110568672
Hepatic enzyme increased 34.94 26.23 3 15877 320889 110252530
Skin tightness 32.63 26.23 16 15864 5597 110567822
Shunt malfunction 32.17 26.23 8 15872 362 110573057
Urticaria 32.09 26.23 4 15876 318853 110254566
Weight decreased 31.34 26.23 14 15866 468043 110105376
Drug ineffective 31.27 26.23 113 15767 1520427 109052992
Joint contracture 30.52 26.23 12 15868 2479 110570940
Swelling 30.39 26.23 115 15765 350926 110222493
Mucosal atrophy 29.66 26.23 6 15874 104 110573315
Blood creatinine increased 28.99 26.23 74 15806 182815 110390604
Transient ischaemic attack 28.06 26.23 40 15840 63942 110509477
Urinary tract infection 26.60 26.23 7 15873 326275 110247144
Ileus 26.34 26.23 27 15853 30702 110542717

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AE03 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Drugs for treatment of hyperkalemia and hyperphosphatemia
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia 10 drugs
calcium acetatecalcium acetate and magnesium carbonatecalcium polystyrene sulfonatecolestilanferric citratepatiromer calciumsevelamersodium polystyrene sulfonatesodium zirconium cyclosilicatesucroferric oxyhydroxide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal Osteodystrophy with Hyperphosphatemia indication
Hyperphosphatemia associated with administration of FGFR inhibitor indication
Constipation contraindication 14760008 DOID:2089
Fecal impaction contraindication 44635007
Intestinal obstruction contraindication 81060008 DOID:8437
Gastrointestinal obstruction contraindication 126765001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4021512 VUID
N0000179691 NUI
54451-24-0 SECONDARY_CAS_RN
4021512 VANDF
CHEBI:750449 CHEBI
CHEMBL2096647 ChEMBL_ID
C119467 MESH_SUPPLEMENTAL_RECORD_UI
DB06792 DRUGBANK_ID
490D9F069T UNII
234416 RXNORM
18979 MMSL
35731 MMSL
62060 MMSL
79763 MMSL
d05395 MMSL
008767 NDDF
414570008 SNOMEDCT_US
414571007 SNOMEDCT_US
C0768119 UMLSCUI
168924 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5938 TABLET, CHEWABLE 500 mg ORAL ANDA 28 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5939 TABLET, CHEWABLE 750 mg ORAL ANDA 28 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5940 TABLET, CHEWABLE 1000 mg ORAL ANDA 28 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-252 TABLET, CHEWABLE 500 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-253 TABLET, CHEWABLE 750 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-254 TABLET, CHEWABLE 1000 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-256 POWDER 750 mg ORAL NDA 31 sections
Fosrenol HUMAN PRESCRIPTION DRUG LABEL 1 54092-257 POWDER 1000 mg ORAL NDA 31 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 66993-422 TABLET, CHEWABLE 500 mg ORAL NDA authorized generic 31 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 66993-423 TABLET, CHEWABLE 750 mg ORAL NDA authorized generic 31 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 66993-424 TABLET, CHEWABLE 1000 mg ORAL NDA authorized generic 31 sections
Lanthanum Carbonate Human Prescription Drug Label 1 67877-256 TABLET, CHEWABLE 500 mg ORAL ANDA 28 sections
Lanthanum Carbonate Human Prescription Drug Label 1 67877-257 TABLET, CHEWABLE 750 mg ORAL ANDA 28 sections
Lanthanum Carbonate Human Prescription Drug Label 1 67877-258 TABLET, CHEWABLE 1000 mg ORAL ANDA 28 sections
Lanthanum Carbonate Human Prescription Drug Label 1 68180-819 TABLET, CHEWABLE 500 mg ORAL ANDA 27 sections
Lanthanum Carbonate Human Prescription Drug Label 1 68180-820 TABLET, CHEWABLE 750 mg ORAL ANDA 27 sections
Lanthanum Carbonate Human Prescription Drug Label 1 68180-821 TABLET, CHEWABLE 1000 mg ORAL ANDA 27 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 69097-934 TABLET, CHEWABLE 500 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 69097-935 TABLET, CHEWABLE 750 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 69097-936 TABLET, CHEWABLE 1000 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 76282-476 TABLET, CHEWABLE 500 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 76282-477 TABLET, CHEWABLE 750 mg ORAL ANDA 30 sections
Lanthanum carbonate HUMAN PRESCRIPTION DRUG LABEL 1 76282-478 TABLET, CHEWABLE 1000 mg ORAL ANDA 30 sections